Clinical trials: Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis Web Based Patient Care Database: ALSConnection.Org
The purpose is to collect data for ALS research. The data will be used to learn more about the origin of ALS and to improve quality of care for people with ALS.
- Trial name
- NCT00302198
- Testing
- ALS Registry
- Where
- United States
- Volunteers
- 15,000 people
- Sponsor
- Forbes Norris MDA/ALS Research Center
Amyotrophic Lateral Sclerosis
Therapeutic Imaging Biomarkers for Amyotrophic Lateral Sclerosis
Study the cervical spinal cord and brain over time to assess changes and differences in subjects with amyotrophic lateral sclerosis.
- Trial name
- NCT02058732
- Testing
- MRI
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Michigan
Amyotrophic Lateral Sclerosis
The Treatment of Amyotrophic Lateral Sclerosis With Huollingshengji Granules
This study intends to evaluate the efficacy and safety of Dong Lingsheng Ji Granule in the treatment of amyotrophic lateral sclerosis (spleen deficiency, kidney-yang deficiency syndrome) in comparison with riluzole, so as to…
- Trial name
- NCT04950933
- Testing
- Huolingshengji Granules, Riluzole tablet
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Peking University Third Hospital
Amyotrophic Lateral Sclerosis
IC14 for ALS Patients Expanded Access
The primary objective is to provide the investigational product, IC14, at the dose of 8 mg/kg intravenously every 2 weeks for 12 weeks to 6 participants with amyotrophic lateral sclerosis (ALS).
- Trial name
- EAP (NCT04309604)
- Testing
- IC14
- Where
- United States
- Sponsor
- Implicit Bioscience
Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP)
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American…
- Conditions
- Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Behavioral Variant Frontotemporal Dementia (bvFTD)
- Trial name
- NCT04363684
- Where
- 26 sites in United States, Canada
- Volunteers
- 2,100 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Amyotrophic Lateral Sclerosis
Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase II, double-blind, randomized, placebo-controlled ascending dose titration study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic effects of multiple ascending doses of CK-2017357 to an individual…
- Trial name
- NCT01486849
- Testing
- CK-2017357, Riluzole 50 MG
- Where
- 11 sites in United States
- Volunteers
- 27 people
- Sponsor
- Cytokinetics
Amyotrophic Lateral Sclerosis
Expression Profile Study of Macrophages From Patients Affected by ALS or Other Related Motor Impairments
The aim of this project is to analyze the macrophage transcriptome and protein markers of Amyotrophic Lateral Sclerosis (ALS) patients compared to controls (non-affected individuals, patients with other motor impairments) and…
- Trial name
- Mac2ALS (NCT04816227)
- Where
- France
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Amyotrophic Lateral Sclerosis
QCT in ALS Diagnosis, Mechanistic Understanding and Follow-up
Multidisciplinary management of amyotrophic lateral sclerosis (ALS) can significantly increase survival but also improve the quality of life of patients.
- Trial name
- PEM-SLA (NCT06284161)
- Testing
- Quadriceps Combined Test
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Clermont-Ferrand
Amyotrophic Lateral Sclerosis
A Study Exploring the PK/PD Relationship of QRL-101 in Adults With ALS
This Phase 1 randomized, placebo-controlled, double-blind study will evaluate the PK/PD relationship of single doses of QRL-101 in 12 ALS participants.
- Trial name
- NCT06714396
- Testing
- QRL-101
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- QurAlis Corporation
Major Depression, Multiple Sclerosis
Escitalopram (Lexapro) for Depression MS or ALS
The purpose of this study is to see if escitalopram (Lexapro) improves symptoms of major depressive disorder in patients who have ALS or MS.
- Conditions
- Major Depression, Multiple Sclerosis, Amyotrophic Lateral Sclerosis
- Trial name
- NCT00965497
- Testing
- escitalopram
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of South Carolina
Amyotrophic Lateral Sclerosis
A 12-week, Multicenter, Safety and Dose-ranging Study of 3 Oral Doses of TCH346 in Patients With Amyotrophic Lateral Sclerosis
This study is the first to be performed in Amyotrophic Lateral Sclerosis (ALS) patients with the novel compound TCH346. Its purpose is to evaluate the safety and clinical effects of 3 dose levels of TCH 346 compared to placebo in…
- Trial name
- NCT00036413
- Testing
- TCH346
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Novartis Pharmaceuticals
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
Genetic Study of Familial and Sporadic ALS/Motor Neuron Disease, Miyoshi Myopathy and Other Neuromuscular Disorders
The investigators laboratory has been studying families with a history of ALS for more than 30 years and is continuing to use new ways to understand how genes may play a role in ALS, motor neuron disease and other neuromuscular…
- Conditions
- Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, PLS, Motor Neuron Disease
- Trial name
- NCT01459302
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Massachusetts, Worcester
Alzheimer's Disease, Mild Cognitive Impairment
Retinal Imaging in Neurodegenerative Disease
This study aims to develop and evaluate biomarkers using non-invasive optical coherence tomography (OCT) and OCT angiography (OCTA) as well as ultra-widefield (UWF) fundus photography to assess the structure and function of the…
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment, Parkinson's Disease, Multiple Sclerosis
- Trial name
- NCT03233646
- Testing
- Retinal and Choroidal Imaging
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Duke University
Amyotrophic Lateral Sclerosis
Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis
This study aims to study the feasibility of psilocybin therapy for patients with Amyotropic Lateral Sclerosis (ALS) with depressed mood.
- Trial name
- NCT06656702
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Johns Hopkins University
Amyotrophic Lateral Sclerosis, ALS
Study of miRNA Expression Pattern as Diagnostic and Prognostic Biomarker in Amyotrophic Lateral Sclerosis
The principal goal is to demonstrate that a specific pattern of microRNA (miRNA) expression can be correlated with the definite diagnostic of Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- MIRSLA (NCT01992029)
- Testing
- Clinical evaluation, Muscular biopsy, Lumbar puncture
- Where
- France
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Amyotrophic Lateral Sclerosis
HEALEY ALS Platform Trial - Regimen G DNL343
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.
- Trial name
- NCT05842941
- Testing
- DNL343
- Where
- United States
- Volunteers
- 249 people
- Sponsor
- Merit E. Cudkowicz, MD
Amyotrophic Lateral Sclerosis (ALS)
Clinical Trial Nuedexta in Subjects With ALS
The purpose of this study is to determine whether Nuedexta is effective in the treatment of symptoms (impaired speech, swallowing, and saliva control)associated with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT01806857
- Testing
- Nuedexta
- Where
- 7 sites in United States
- Volunteers
- 90 people
- Sponsor
- Center for Neurologic Study, La Jolla, California,
Familial Amyotrophic Lateral Sclerosis
Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations
This study will test the safety, tolerability and pharmacokinetics of single doses of ISIS 333611 administered into the spinal canal as 12 hour infusions.
- Trial name
- SOD-1 (NCT01041222)
- Testing
- ISIS 333611
- Where
- 4 sites in United States
- Volunteers
- 33 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Amyotrophic Lateral Sclerosis
Autologous Cultured Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in ALS Patients.
The study will evaluate the safety, tolerability and therapeutic effects (preliminary efficacy) of injection of autologous cultured mesenchymal bone marrow stromal cells secreting neurotrophic factors (MSC-NTF), as a possible…
- Trial name
- NCT01051882
- Testing
- MSC-NTF cells transplantation (IM), MSC-NTF cells transplantation (IT)
- Where
- Israel
- Volunteers
- 12 people
- Sponsor
- Brainstorm-Cell Therapeutics
Amyotrophic Lateral Sclerosis
A Multicenter Phase I/II Clinical Trial to Evaluate Safety of Mesenchymal Stem Cell in Patients With Amyotrophic Sclerosis Lateral
A multicenter phase I/II Clinical trial,randomized, controlled with placebo, triple blind to evaluate the safety of the intravenous administration of 3 doses of autologous mesenchymal stem cells cells from adipose tissue in…
- Trial name
- NCT02290886
- Testing
- Intravenous administration of 1 million of MSC, Intravenous administration of 2 million of MSC, Intravenous administration of 4 million of MSC
- Where
- 4 sites in Spain
- Volunteers
- 52 people
- Sponsor
- Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud